453 related articles for article (PubMed ID: 28044941)
21. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
24. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
[TBL] [Abstract][Full Text] [Related]
25. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
26. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Dawood M; Elbadawi M; Böckers M; Bringmann G; Efferth T
Biomed Pharmacother; 2020 Sep; 129():110454. PubMed ID: 32768947
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
30. The histone deacetylase-6 inhibitor tubacin directly inhibits de novo sphingolipid biosynthesis as an off-target effect.
Siow D; Wattenberg B
Biochem Biophys Res Commun; 2014 Jul; 449(3):268-71. PubMed ID: 24835950
[TBL] [Abstract][Full Text] [Related]
31. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
[TBL] [Abstract][Full Text] [Related]
32. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
33. Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio)Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study.
Abdulwahab HG; Mansour RE; Farghaly TA; El-Sehrawi HM
Bioorg Chem; 2024 May; 146():107284. PubMed ID: 38493640
[TBL] [Abstract][Full Text] [Related]
34. Novel benzimidazole-linked (thio)barbiturates as non-hydroxamate HDAC6 inhibitors targeting leukemia: Design, synthesis, and structure-activity relationship.
Mansour RE; Abdulwahab HG; El-Sehrawi HM
Arch Pharm (Weinheim); 2023 Jun; 356(6):e2200433. PubMed ID: 36942938
[TBL] [Abstract][Full Text] [Related]
35. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
36. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
[TBL] [Abstract][Full Text] [Related]
37. Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines.
Nencetti S; Cuffaro D; Nuti E; Ciccone L; Rossello A; Fabbi M; Ballante F; Ortore G; Carbotti G; Campelli F; Banti I; Gangemi R; Marshall GR; Orlandini E
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):34-47. PubMed ID: 33100043
[TBL] [Abstract][Full Text] [Related]
38. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
[TBL] [Abstract][Full Text] [Related]
39. Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety.
Bui HTB; Nguyen PH; Pham QM; Tran HP; Tran Q; Jung H; Hong QV; Nguyen QC; Nguyen QP; Le HT; Yang SG
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408604
[TBL] [Abstract][Full Text] [Related]
40. Quinazoline-chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in-silico studies of potential anticancer activity against multiple myeloma.
Mansour MA; AboulMagd AM; Abbas SH; Abdel-Aziz M; Abdel-Rahman HM
Arch Pharm (Weinheim); 2024 May; 357(5):e2300626. PubMed ID: 38297894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]